90068-86-3

Usage

Uses

Used in Perfume and Cosmetic Industry:
Hexanoic acid, 6-[(3-phenylpropyl)amino]-, methyl ester is used as a fragrance ingredient in perfumes and cosmetics for its pleasant, fruity scent.
Used in Food Industry:
It is also used as a flavoring agent in food products to enhance their taste and aroma.
Used in Pharmaceutical Industry:
Hexanoic acid, 6-[(3-phenylpropyl)amino]-, methyl ester has been studied for its potential pharmaceutical applications, particularly in the treatment of neurological disorders.
However, it is important to handle Hexanoic acid, 6-[(3-phenylpropyl)amino]-, methyl ester with care, as it can be irritating to the skin, eyes, and respiratory system, and can be harmful if ingested or inhaled in large amounts.

Upstream product

• 14273-90-6 methyl 6-bromohexanoate 
• 2038-57-5 3-Phenylpropan-1-amine 
• 104-53-0 3-phenyl-propionaldehyde 
• 1926-80-3 methyl 6-aminocaproate hydrochloride 

Downstream Products

• 1235975-94-6 6-(3-phenyl-propylamino)-hexanoic acid methyl ester trifluoroacetic acid 

Relevant academic research and scientific papers

TERTIARY AMIDES AND METHOD OF USE

Compunds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity

Thirty-six novel acylurea connected straight chain hydroxamates were designed and synthesized. Structure-activity relationships (SAR) were established for the length of linear chain linker and substitutions on the benzoylurea group. Compounds 5g, 5i, 5n, and 19 showed 10-20-fold enhanced HDAC1 potency compared to SAHA. In general, the cellular potency pIC50 (COLO205) correlates with enzymatic potency pIC50 (HDAC1). Compound 5b (SB207), a structurally simple and close analogue to SAHA, is more potent against HDAC1 and HDAC6 compared to the latter. As a representative example of this series, good in vitro enzymatic and cellular potency plus an excellent pharmacokinetic profile has translated into better efficacy than SAHA in both prostate cancer (PC3) and colon cancer (HCT116) xenograft models.